PSIAC

Literaturverzeichnis

Erweiterte Suche
Zo'o M. Pediatr Radiol. Nov 2011; 41(11): 1393-400 Pubmed [4918]
Zoccali et al. (2007) J Clin Psychopharmacol 93:109-116 [1144]
Zoccali R. Pharmacol Res. Oct 2003; 48(4): 411-4 Pubmed [2545]
Zoleptil (Zotepine) Knoll Limited . Summary of product characteristics, Novembet 2001 [2504]
Zoleptil (Zotepine) Knoll Limited . Summary of product characteristics. November 2001 [2078]
Zoleptil (Zotepine) Knoll Limited . Summary of product characteristics., November 2001 [1646]
Zoleptil (Zotepine) Knoll Limited . Summary of product characteristics., Novembet 2001 [945]
Zoleptil (Zotepine). Knoll Limited. Summary of product characteristics, November 2001 [2515]
Zong J. J Int AIDS Soc. Nov 2014; 17(4 Suppl 3): 19584 Pubmed [6639]
Zor M. Int Urogynecol J. Jul 2015; 26(7): 959-66 Pubmed [8295]
Zubieta, Demitrack. J Clin Pharmacol (1991) 11, 327-328 [1336]
Zubillaga I. Endocrinol Diabetes Nutr. Jan 2017; 64(6): 338-339 Pubmed [6373]
Zullino DF. Drugs Today (Barc). Jul 2004; 40(7): 603-19 Pubmed [4174]
Zullino DF. Int Clin Psychopharmacol. May 2002; 17(3): 141-3 Pubmed [1193]
Zumoff B. JAMA. May 1977; 237(18): 1960-1 Pubmed [792]
Zung S. Braz J Psychiatry. Mar 2006; 28(1): 84-5 Pubmed [8639]
Zuo R. Drug Metab Dispos. Feb 2017; 45(2): 198-207 Pubmed [7586]
Zusammenfassung der zur Zulassung eingereichten Klinischen Studien: ZHANG, J: FDA Clinical Review of Olanzapine Pamoate Depot in the Treatment of Schizophrenie: http://www.fda.gov/ohrms/dockets/AC/08/slides/2008-4338s1-01-FDA-Zhang_files/frames.htm [3029]
Zwanzger P. J Clin Psychiatry. Mar 2001; 62(3): 208-9 Pubmed [1672]
Zweers-Zeilmaker WM. Xenobiotica. Aug 1997; 27(8): 769-80 Pubmed [4510]
Zylber-Katz E. Ann Pharmacother. Feb 1995; 29(2): 127-31 Pubmed [6005]
Zylber-Katz E. Drug Intell Clin Pharm. Jun 1988; 22(6): 504-5 Pubmed [5573]